Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
134 hedge funds and large institutions have $828M invested in Revance Therapeutics, Inc. in 2019 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 49 increasing their positions, 27 reducing their positions, and 14 closing their positions.
179% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 14
81% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 27
49% more capital invested
Capital invested by funds: $554M → $828M (+$274M)
23% more funds holding
Funds holding: 109 → 134 (+25)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
21% less call options, than puts
Call options by funds: $1.65M | Put options by funds: $2.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$21.2M |
| 2 |
DM
Deerfield Management
New York
|
+$14M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$13M |
| 4 |
PA
Perceptive Advisors
New York
|
+$12.7M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$11.6M |
| 2 |
SCM
Sio Capital Management
New York
|
-$3.38M |
| 3 |
Renaissance Technologies
New York
|
-$3.08M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2.82M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.06M |
RVNC Hedge Fund Activity: Q4 2019 in Review
134 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2019, worth a combined $828M — up 49% from $554M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new RVNC positions and 14 closed out — a net gain of 25 holders — while 49 added to existing stakes and 27 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $21.2M. The largest seller was Bank of New York Mellon, cutting an estimated $11.6M.
- 134 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2019, up from 109 in Q3 2019.
- Funds reported $828M of Revance Therapeutics, Inc. stock for Q4 2019, up 49% quarter-over-quarter.
- 39 funds opened new Revance Therapeutics, Inc. positions in Q4 2019 and 14 closed out, a net change of +25 holders.
- The largest Revance Therapeutics, Inc. buyer in Q4 2019 was JP Morgan Chase, an estimated $21.2M added.
- The largest Revance Therapeutics, Inc. seller in Q4 2019 was Bank of New York Mellon, an estimated $11.6M sold.
Based on aggregated 13F filings for Q4 2019.